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ABSTRACT
Objective: To investigate multimorbidity transitions
from general practice populations across healthcare
interfaces and the associated healthcare costs.
Design: Clinical-linkage database study.
Setting: Population (N=60 660) aged 40 years and over
registered with 53 general practices in Stoke-on-Trent.
Participants: Population with six specified
multimorbidity pairs were identified based on
hypertension, diabetes mellitus (DM), coronary heart
disease (CHD), chronic obstructive pulmonary disease
(COPD), congestive heart failure (CHF) and chronic
kidney disease (CKD).
Main outcomes measures: Chronic disease
registers were linked to accident and emergency (A&E)
and hospital admissions for a 3-year time period
(2007–2009), and associated costs measured by
Healthcare Resource Groups. Associations between
multimorbid groups and direct healthcare costs were
compared with their respective single disease groups
using linear regression methods, adjusting for age,
gender and deprivation.
Results: In the study population, there were 9735
patients with hypertension and diabetes (16%), 3574
with diabetes and CHD (6%), 2894 with diabetes and
CKD (5%), 1855 with COPD and CHD (3%), 754 with
CHF and COPD (1%) and 1425 with CHF and CKD
(2%). Transition, defined as at least one episode in
each of the 3-year time periods, was as follows:
patients with hypertension and DM had the fewest
transitions in the 3-year time period (37% A&E
episode and 51% hospital admission), but those with
CHF and CKD had the most transitions (67% A&E
episode and 79% hospital admission). The average
3-year total costs per multimorbid patient for A&E
episodes ranged from £69 to £166 and for hospital
admissions ranged from between £2289 and £5344.
The adjusted costs were significantly higher for all six
multimorbid groups compared with their respective
single disease groups.
Conclusions: Specific common multimorbid pairs are
associated with higher healthcare transitions and
differential costs. Identification of multimorbidity type
and linkage of information across interfaces provides
opportunities for targeted intervention and delivery of
integrated care.
ARTICLE SUMMARY
Article focus
▪ In the population, there are large numbers of
people who suffer from two or multiple chronic
diseases at the same time.
▪ Most of the current evidence has focused on the
impact of multimorbidity on health status and
very few have investigated the transitions across
healthcare and the associated costs.
▪ While individual chronic diseases have been
shown to be associated with high healthcare
costs, whether specific multimorbid combina-
tions have differential healthcare transitions and
healthcare costs is unknown.
Key messages
▪ Specific multimorbid pairs are associated with
different levels of healthcare transitions and
costs relating to accident and emergency and
hospital admissions.
▪ Chronic disease pairs indicate the population-
level multimorbidity ‘severity’, as indicated by
transitions and costs, with a range from diabetes
and hypertension (‘low severity’), diabetes and
heart disease, diabetes and chronic kidney
disease (CKD), chronic obstructive pulmonary
disease (COPD) and heart disease, heart failure
and COPD, to heart failure and CKD (‘high
severity’).
▪ Identification of multimorbidity type and linkage
of information across healthcare interfaces pro-
vides opportunities for targeted intervention and
delivery of cost-effective integrated care.
Strengths and limitations of this study
▪ The study was based on large-scale data linking
chronic disease registers from general practices
to accident and emergency episodes and hospital
admissions.
▪ The study highlights the innovative potential of
linkage data between healthcare interfaces to
inform healthcare delivery.
▪ The study uses a specific but limited number of
common chronic diseases to illustrate the
approach to using linked data within a single
large region of the UK.
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BACKGROUND
Multimorbidity is an individual’s experience of two or
more illnesses at the same time. In ageing populations,
the numbers of people with such multimorbidity will
increase substantially, and it is estimated that there are
up to 20% of the British population (4 million people)
who may experience such multimorbidity,1 with a pro-
jected further increase of 37% in the England and
Wales population aged 50 years and over by the year
2031. This means that the current focus of healthcare
delivery on speciﬁc disease-focus outcomes will have to
be complemented by a Public Health priority focusing
on multimorbidity in older populations.
Current evidence on multiple disease in the same
person has shown that this is a common problem, which
has a high impact on an individual’s health and on the
use of healthcare resources.2–4 However, people may also
experience transitions, that is, healthcare changes from
general practice to different healthcare interfaces such
as Accident and Emergency (A&E) or hospital care,
especially as delivery of chronic disease is orientated
around individual healthcare pathways. Once a person
experiences a number of different diseases, the issue
then becomes how the person interacts with different
healthcare interfaces. Current research has shown that
in speciﬁc settings, such as general practice5 or hospitals,
multimorbidity is common in the encounters that are
present in the disease-care pathways.6 7 However, there
are little empirical data on how multimorbidity inﬂu-
ences transitions across different healthcare interfaces
and whether speciﬁc multimorbidity combinations are
more likely to be associated with higher healthcare pre-
sentations, such as A&E episodes or hospital admissions.
Routine coding of such patients’ encounters now occurs
in clinical practice, A&E and hospitals, and techno-
logical developments allow the linkage of clinical infor-
mation across these interfaces.8 These developments
allow for the potential for targeted prevention and new
models of healthcare interventions for patients who
experience multiple chronic diseases at the same time.
The other key area of focus is how cost-effective care
pathways can be developed. By understanding how mul-
timorbidity inﬂuences interface presentation and the
associated healthcare costs, it can be explored as to
whether healthcare costs can be ‘benchmarked’ for spe-
ciﬁc conditions and combinations of conditions.9
Currently, much of the chronic disease healthcare deliv-
ery pathways has aligned along single-disease lines, for
example, diabetes, chronic obstructive airways disease or
heart failure. So the potential range of multimorbidity
model of care could range from joint clinics (eg, dia-
betes and renal) to the holistic clinical assessment con-
ducted by elderly care physicians.10 11 However, one
could argue that the next simple step from single
disease pathway care to a multimorbidity approach is
understanding pair combinations which link to at least
two individual disease care pathways, and which we use
in this study by selecting common chronic diseases in
the older population. Using a large linkage dataset, we
investigated the clinical hypothesis as to whether speciﬁc
chronic disease multimorbidity pairs are associated with
differences in healthcare transitions and associated
healthcare costs, and compared it with populations with
only one of the respective matched conditions.
METHODS
Design
The design of the study was a cross-sectional clinical
linkage study of the population aged 40 years and over
on chronic disease registers to transition data on A&E
episodes or hospital admission in a 3-year time period (1
January 2007 to 31 December 2009).
Setting
The setting is an urban population of around 240 000
which focuses around the city of Stoke-on-Trent, which
is one of the most deprived in England and Wales and
has some of the highest levels of chronic disease preva-
lence, and over half of the areas are in the most
deprived 20% in England.12
Clinical linkage datasets
Chronic disease registers
The local Primary Care Trust oversees 53 general prac-
tices, all of which have been participating in a national
and local quality improvement framework13 for speciﬁc
chronic diseases, as well as in recording clinical data
through regular data audits and checks. For speciﬁed
conditions, using the Read Code classiﬁcation,14 general
practitioners and their teams had recorded clinical data
on disease registers for their population. These practices
contributed to the construction of a clinical database,
which for this study covers a 3-year time period. From
this database, all adults on chronic disease registers for
the following six conditions were identiﬁed: hyperten-
sion (HT), diabetes mellitus (DM), coronary heart
disease (CHD), chronic obstructive pulmonary disease
(COPD), chronic heart failure (CHF) and chronic
kidney disease (CKD).
Multimorbidity definitions
While multimorbidity could be characterised for the
study as any number or multiple combinations, we
selected ‘pairs’ as the basic measure of investigating mul-
timorbidity. The ‘pairs’ measure provides the basis for
clinically intuitive understanding of how two chronic
disease pathways might combine together, but with six
studies of chronic diseases chosen, the potential number
of pairs could be 6×6=36. Therefore, six example pairs
were chosen to represent the range of chronic diseases
onsets from midlife to old age and included: (1) DM
and HT; (2) DM and CHD; (3) DM and CKD; (4)
COPD and CHD; (5) COPD and CHF and (6) CHF and
CKD. These multimorbid pairs were then compared
with their respective ‘index’ conditions, for example,
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HT and DM multimorbidity was compared with the
group with HT without DM (expressed as HT+ DM−)
and DM without HT (DM+ HT−). Each multimorbid
group and their respective ‘index’ conditions represent
a within group (see table 1 for annotation of all study
deﬁned groups) and separate clinical hypothesis of the
association between multimorbidity and healthcare out-
comes. While this ‘multimorbid pairs’ approach means
that there might be overlap between different pair
groups, each study group had been selected by common
conditions of interest, and not in relation to other multi-
morbidity that might be present or absent.
In addition to age and gender data available from the
general practice records, the Index of Multiple
Deprivation (IMD) was used as a measure of socio-
economic status.
IMD is a measure of multiple deprivation at the small
area level.15 Based on the Census data, the score com-
bines a number of indicators, including economic,
social and housing issues, into a single deprivation score
for each small area in England.
Healthcare transitions data: A&E episodes and hospital
admissions
Using the unique National Health Service (NHS)
Number allocated to an individual patient, a dataset was
created linking their clinical data from general practice
to any other information such as A&E attendance and
hospital admissions (planned and unplanned) for the
time period 1 January 2007 to 31 December 2009. The
total number of attendances in the study time period for
each A&E type including minor injury units and walk-in
centres were included. While there are a number of hos-
pital providers within the region, the single major
provider of emergency and acute hospital services for
the city is the University Hospital of North Staffordshire
NHS Trust. Hospital admissions were based on Hospital
Episode Statistics, which contain records for all NHS
patients admitted to any English hospitals in each ﬁnan-
cial year. These A&E and hospital data are the means by
which Primary Care (PCT) Commissioners arrange
payment from the purchaser to the acute hospital Trust
provider.16 Linking these clinical databases makes it pos-
sible to track the healthcare patterns of individual
patients. We therefore used these data to establish the
natural history of patients with multimorbidity and tran-
sitions across the A&E and hospital interfaces.
Healthcare transitions cost
For each transition activity, the allocated Healthcare
Resource Group (HRG) was used as a measure of cost
for an A&E episode or a hospital admission in the 3-year
time period. An HRG is a group of clinically similar
treatments and care that requires similar levels of health-
care resource. It allows commissioners to understand
their activity in terms of the types of patients they care
for and the treatments they undertake.17 18 HRGs are
currently used as a means of determining the costs for
individual patients in each ﬁnancial year, depending on
their healthcare use. From the individual-level HRG cost
data for A&E episodes or hospital admission, data were
aggregated to the population-level costs for the speciﬁed
multimorbidity groups for the whole of the 3-year time
period. Individual-level data were anonymised by the
Public Health Intelligence Team and subsequently
linked for analyses using a study identiﬁer by the project
team, and provision of the anonymous data was made
under existing service agreements.
Table 1 Study groups
Annotation Study groups
HT+ DM− Hypertension without diabetes mellitus
DM+ HT− Diabetes mellitus without hypertension
HT and DM Multimorbidity of hypertension and diabetes mellitus
DM+ CHD− Diabetes mellitus without coronary heart disease
CHD+ DM− Coronary heart disease without diabetes mellitus
DM and CHD Multimorbidity of diabetes mellitus and coronary heart disease
DM+ CKD− Diabetes mellitus without chronic kidney disease
CKD+ DM− Chronic kidney disease without diabetes mellitus
DM and CKD Multimorbidity of diabetes mellitus and chronic kidney disease
COPD+ CHD− Chronic obstructive pulmonary disease without coronary heart disease
CHD+ COPD− Coronary heart disease without chronic obstructive pulmonary disease
COPD and CHD Multimorbidity of chronic obstructive pulmonary disease and coronary heart disease
COPD+ CHF− Chronic obstructive pulmonary disease without chronic heart failure
CHF+ COPD− Chronic heart failure without chronic obstructive pulmonary disease
CHF and COPD Multimorbidity of chronic heart failure and chronic obstructive pulmonary disease
CHF+ CKD− Chronic heart failure without chronic kidney disease
CKD+ CHF− Chronic kidney disease without chronic heart failure
CKD and CHF Multimorbidity of chronic kidney disease and chronic heart failure
CHD,coronary heart disease; CHF, chronicheart failure; CKD,chronic kidney disease; COPD,chronic obstructive pulmonary disease; DM,
diabetes mellitus; HT,hypertension.
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Analyses
The multimorbidity populations are described by age
bands (40–49, 50–59, 60–69, 70–79, 80–89, 90 years and
over), gender and deprivation. The IMD score for the
study population was summarised into quartiles ranging
from quartiles 1 (least deprived) to 4 (most deprived).
The sociodemographic prevalence pattern for the study
multimorbidity pairs and respective index conditions,
including the population without index condition, was
also estimated and information is given in online supple-
mentary tables S1–S3.
Interface transitions for the six multimorbid groups
and their respective index conditions were deﬁned as
follows. A&E transitions were ﬁrst summarised as at least
one episode in any one of the 3 years, and so does not
include multiple episodes within the same year. A similar
approach was used for summarising the hospital admis-
sions. χ² Tests were used to assess trends in the association
between study deﬁned groups and recurrent A&E epi-
sodes and hospital admissions (deﬁned as at least one in
each of the 3 years). These data are then presented as
counts measured from 0 (no episodes or admissions), 1
(one episode in any one of the 3 years), 2 (two episodes
in any two of the 3 years) and 3 (at least one episode in
all 3 years). Analysis of variance and analysis of covariance
with actual age, gender and IMD as covariates were used
to estimate the signiﬁcance of mean differences of the
number of A&E episodes, hospital admissions and costs
within each of the multimorbid groups, comparing the
pairs of diseases to their respective index diseases.
Total costs for the study time period were estimated
for each individual patient who had any A&E episode or
hospital admissions, and here the total costs relate to all
A&E episodes and hospital admissions over the 3-year
time period. Using linear regression methods, the
difference in total cost per patient over the 3 years for
each multimorbid group was compared with the respect-
ive index conditions assessed, adjusting for age, gender
and deprivation. Within each of the six multimorbid
groups, the regression coefﬁcient was tested for signiﬁ-
cance differences from their respective reference cat-
egory with cost allocation as zero (0).
RESULTS
From a study population of 60 660 patients aged 40 years
and over on speciﬁc chronic disease registers in a 3-year
time period, there were 9735 patients with HT and DM
(16%), 3574 with DM and CHD (6%), 2894 with DM
and CKD (5%), 1855 with COPD and CHD (3%), 754
with CHF and COPD (1%) and 1425 with CHF and
CKD (2%). The sociodemographic prevalence ﬁgures
for the multimorbidity pair groups and comparator
groups are given in online supplementary tables S1–S3.
Sociodemographic characteristics of multimorbid pairs
Multimorbid pairs, which included DM and HT or CHD,
showed age-related differences (table 2). Within the DM
and CKD multimorbid group, there was a higher pro-
portion of older patients aged 70 years and over (51%)
than within the DM and CHD group or the HT and DM
multimorbid group. There were more women (64%)
than men within the DM and CKD group, than the
other two DM multimorbid groups, but the deprivation
distributions were similar. Within the COPD and CHF
multimorbid group, there was a higher proportion of
older patients aged 70 years and over (75%), compared
with COPD and CHD group, but within the COPD and
CHD group there were more men (62%) than women.
The CHF and CKD multimorbid group had the highest
Table 2 Sociodemographic characteristics of the multimorbid study pairs
Groups
HT and DM
N (%)
(n=9735)
DM and CHD
N (%)
(n=3574)
DM and CKD
N (%)
(n=2894)
CHD and COPD
N (%)
(n=1855)
CHF and COPD
N (%)
(n=754)
CHF and CKD
N (%)
(n=1425)
40–49 years 866 (8.9) 152 (4.2) 48 (1.7) 22 (1.2) 4 (0.5) 6 (0.4)
50–59 years 2043 (21.0) 533 (14.9) 227 (7.8) 179 (9.6) 42 (5.5) 49 (3.4)
60–69 years 2866 (29.4) 1067 (29.8) 645 (22.3) 499 (26.8) 140 (18.6) 177 (12.4)
70–79 years 2686 (27.6) 1219 (34.1) 1200 (41.3) 710 (38.3) 298 (39.3) 488 (34.2)
80–89 years 1152 (11.9) 552 (15.5) 691 (24.0) 409 (22.1) 236 (31.6) 594 (41.9)
90 years and over 122 (1.3) 51 (1.5) 83 (2.9) 36 (2.0) 34 (4.5) 111 (7.7)
Men 5016 (51.5) 2162 (60.4) 1055 (36.4) 1152 (62.1) 427 (56.4) 549 (38.5)
Women 4719 (48.5) 1412 (39.6) 1839 (63.6) 703 (37.9) 327 (43.6) 876 (61.5)
Quartile 1*
Least deprived
2044 (21.1) 691 (19.5) 596 (20.7) 249 (13.5) 109 (14.5) 300 (21.1)
Quartile 2 2335 (24.1) 785 (22.1) 652 (22.6) 428 (23.2) 171 (22.8) 340 (23.9)
Quartile 3 2541 (26.2) 934 (26.3) 801 (28.9) 527 (28.5) 205 (27.3) 401 (28.2)
Quartile 4
Most deprived
2768 (28.6) 1142 (32.2) 831 (28.9) 644 (34.8) 265 (35.3) 379 (26.7)
*Deprivation measured using the Index of Multiple Deprivation.
CHD, coronary heart disease; CHF, chronic heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease;
DM, diabetes mellitus; HT, hypertension.
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proportion of patients who were aged 80 years and over
(50%), and this group had more women than men.
Multimorbidity transitions across the A&E interface
Patients with HT and DM had the highest proportion
without an A&E episode in the 3-year time period
(63%), whereas patients with CKD and CHF had the
lowest proportion without an A&E episode in the 3-year
time period (33%; table 3). The same ﬁgures for other
multimorbid groups were as follows: DM and CHD 52%;
DM and CKD 51%; COPD and CHD 44% and CHF and
COPD 42%.
The proportion of patients with recurrent A&E epi-
sodes (deﬁned as at least one episode in each of the
3 years) for multimorbid groups was as follows: HT and
DM 2%, DM and CHD 4%, DM and CKD 3%, COPD
and CHD 5%, CHF and COPD 7% and CKD and CHF
6%. These associations and increases across groups were
even more evident for patients who had had an A&E
episode in any two of the 3 years (table 3).
For all six groups, when multimorbid pairs were com-
pared with their respective index condition, there was
an increasing and highly signiﬁcant trend in the associ-
ation between multimorbidity and recurrent A&E epi-
sodes (p<0.001).
Multimorbidity transitions across hospital admission
interface
Patients with HT and DM had the highest proportion
without a hospital admission in the 3-year time period
(49%), but patients with CKD and CHF had the lowest
proportion without a hospital admission in the 3-year
time period (21%; table 3). The same ﬁgures for other
multimorbid groups were as follows: DM and CHD 39%;
DM and CKD 37%; COPD and CHD 31% and CHF and
COPD 28%.
The proportion of patients with recurrent hospital
admissions (deﬁned as at least one in each of the 3 years)
for multimorbid groups was as follows: HT and DM 6%;
DM and CHD 10%; DM and CKD 10%; COPD and CHD
12%; CHF and COPD 13% and CKD and CHF 13%.
These associations and increases across groups were even
more evident for patients who had had a hospital admis-
sion in any two of the 3 years (table 3).
For all six groups, when multimorbid pairs were com-
pared with their respective index conditions, there was
an increasing and highly signiﬁcant trend in the associ-
ation between multimorbidity and higher hospital admis-
sion (p<0.001).
Healthcare costs at the A&E transition
Patients with HT and DM had the lowest mean A&E
costs in the 3-year time period (total £69), but the
highest ﬁgure was for patients with CHF and COPD or
CKD (around £166; table 4). The same ﬁgures for other
multimorbid groups were as follows: DM and CHD £104;
DM and CKD £105; COPD and CHD £138; and CHF
and COPD £164.
Adjusting for age, gender and deprivation still showed
that each of the six multimorbid groups had signiﬁcantly
higher A&E costs than their respective index diseases.
When associations between multimorbid groups and
costs were adjusted, there were two notable groups. The
A&E costs were £13 lower for the index CHD group
compared with the index COPD group, and £31 lower
for the index CKD group than the CHF group (table 3).
For all six groups, when multimorbid pairs were com-
pared with their respective index conditions, there was
an increasing and highly signiﬁcant trend in the associ-
ation between multimorbidity and higher A&E costs
(p<0.001).
Healthcare costs at the hospital admission transition
Patients with HT and DM had the lowest mean hospital
admissions costs in the 3-year time period (total £2289),
but patients with CHF and CKD had the highest costs
(£5344; table 4). The same ﬁgures for the other multi-
morbid groups were as follows: DM and CHD £3372;
DM and CKD £3642; COPD and CHD £3992; and CHF
and COPD £4901.
Adjusting for age, gender and deprivation still showed
that each of the six multimorbid groups had signiﬁcantly
higher hospital admission costs than their respective
index diseases. When associations between multimorbid
groups and costs were adjusted, there were two notable
groups. The hospital admission costs were £152 lower
for the index CHD group compared with the index
COPD group, and £629 lower for the index CKD group
than the CHF group (table 4). For all six groups, when
multimorbid pairs were compared with their respective
index conditions, there was an increasing and highly sig-
niﬁcant trend in the association between multimorbidity
and higher hospital admission costs (p<0.001).
The six multimorbid groups were selected on the basis
of age-related onsets. However, comparing the ﬁndings
for the six multimorbid pairs, after age adjustment, also
showed that these groups can be placed into an order of
an increasing association between the ‘severity’ of multi-
morbid pairs and the likelihood of A&E episodes and
associated costs, or hospital admissions and associated
costs over the 3-year time period. The ‘severity’ of
healthcare impact can be ordered as follows: DM and
HT (‘low severity’), DM and CHD, DM and CKD, COPD
and CHD, CHF and COPD, and CHF and CKD (‘high
severity’; tables 3 and 4).
DISCUSSION
Our large-scale study in a chronic disease population
showed that patients with speciﬁc multimorbidity pairs
had distinct variations in healthcare transitions and in
the associated healthcare costs. While age is a speciﬁc
indicator for the type of multiple chronic disease, adjust-
ment for sociodemographic factors still showed that spe-
ciﬁc multimorbidity pairs were associated with a higher
number of healthcare transitions compared with their
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Table 3 Multimorbidity transitions across A&E and hospital admission interface over 3 years
Study groups*
A&E episodes Hospital admissions
0 1 2 3 0 1 2 3
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%)
HT+ DM− 26 019(68.6) 8903 (23.5) 2466 (6.5) 548 (1.4) 21 957 (54.0) 10 443 (27.5) 4223 (11.1) 1313 (3.5)
DM+ HT− 2733 (63.2) 1154 (26.4) 372 (8.4) 96 (2.1) 2343 (54.0) 1192 (27.5) 601 (13.8) 204 (4.7)
HT and DM 6168 (63.4) 2581 (26.5) 776 (8.0) 210 (2.2) 4800 (49.3) 2888 (29.7) 1456 (15.0) 591 (6.1)
DM+ CHD− 7048 (67.1) 2580 (24.6) 703 (6.7) 170 (1.6) 5766 (54.9) 2993 (28.2) 1403 (12.7) 490 (4.2)
CHD+ DM− 6223 (57.6) 3175 (29.4) 1133 (10.5) 276 (2.6) 4842 (44.8) 3482 (32.2) 1813 (16.8) 670 (6.2)
DM and CHD 1863 (52.1) 1145 (32.0) 436 (12.2) 130 (3.6) 1377 (38.5) 1123 (31.4) 721 (20.2) 353 (9.9)
DM+ CKD− 7440 (66.5) 2761 (24.7) 775 (6.9) 205 (1.8) 6083 (54.4) 3142 (28.1) 1438 (12.9) 518 (4.6)
CKD+ DM− 5137 (57.3) 2733 (30.5) 893 (10.0) 195 (2.2) 3923 (43.8) 3056 (34.1) 1502 (16.8) 477 (5.3)
DM and CKD 1471 (50.8) 964 (33.3) 364 (12.6) 95 (3.3) 1060 (36.6) 938 (32.4) 619 (21.4) 277 (9.6)
COPD+ CHD− 3013 (56.8) 1568 (29.6) 546 (10.3) 177 (3.3) 2443 (46.1) 1665 (31.4) 843 (15.9) 353 (6.7)
CHD+ COPD− 7267 (58.0) 3689 (29.5) 1261 (10.1) 309 (2.5) 5641 (45.0) 3973 (31.7) 2108 (16.8) 804 (6.4)
COPD and CHD 819 (44.2) 631 (34.0) 308 (16.6) 97 (5.2) 578 (31.2) 632 (34.1) 426 (23.0) 219 (11.8)
COPD+ CHF− 3519 (54.9) 1940 (30.3) 723 (11.3) 223 (3.5) 2810 (43.9) 2018 (31.5) 1102 (17.2) 475 (7.4)
CHF+ COPD− 1346 (46.7) 990 (34.3) 440 (15.3) 108 (3.7) 978 (33.9) 996 (34.5) 645 (22.4) 265 (9.2)
CHF and COPD 313 (41.5) 259 (34.4) 131 (17.4) 51 (6.8) 211 (28.0) 279 (37.0) 167 (22.1) 97 (12.9)
CHF+ CKD− 1173 (53.0) 665 (30.0) 295 (13.3) 80 (3.6) 884 (39.9) 737 (33.3) 414 (18.7) 178 (8.0)
CKD+ CHF− 6122 (58.7) 3113 (29.9) 981 (9.4) 211 (2.0) 4678 (44.9) 3456 (33.1) 1723 (16.5) 570 (5.5)
CKD and CHF 481 (33.4) 595 (41.3) 284 (19.7) 80 (5.6) 305 (21.4) 538 (37.8) 398 (27.9) 184 (12.9)
*Minus sign indicates absence of disease and positive sign indicates presence.
A&E, accident and emergency; CHD, coronary heart disease; CHF, chronic heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus;
HT, hypertension.
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respective index groups. Furthermore, these multimor-
bidity associations suggest that they can be ordered into
a ‘severity of healthcare impact’, after adjusting for age.
In this spectrum, a multimorbidity such as HT and dia-
betes represents one end of the healthcare cost spec-
trum, and chronic heart failure and CKD represent the
higher and more costly end of healthcare impact.
The implications of this multimorbidity study covering
a 3-year time period relate to the number and costs of
transitions. The study shows that patients with speciﬁc
multimorbidity have a higher number of annual A&E
episodes or hospital admissions and costs, which means
that this provides a potential mechanism for targeting
patients for intervention across the healthcare interfaces.
Since this information could potentially be linked across
the interface, it also provides the basis for intervention
once initial transitions have occurred to prevent future
unnecessary transitions from general practice to A&E or
hospital admission.
The study was based on large-scale data available from
53 general practices in one of the most deprived regions
in England and over a long-term time period of 3 years.
The current national quality improvement approaches
have been based on establishing chronic disease regis-
ters in clinical practice and aim at improving care for
the individual patient.12 19 However, such registers also
provide the basis for deﬁning population-level impacts
and for providing the integration between public health
prevention (general practice or local area) and
individual-level care. The deﬁnition of multimorbidity,
focusing on ‘pairs’, also means that it allows easier inter-
pretation of the current individual pathways of care and
begins to provide insight into how these might be inte-
grated. For example, HT, diabetes and CHD are often
jointly managed in general practice, but in healthcare
transitions, specialist care could be delivered by nephrol-
ogy (HT), diabetes or cardiology. However, in severe
chronic disease states, such as COPD, CHF and CKD,
which are often jointly managed between general prac-
tice and hospital-based care, such a ‘multimorbidity
pair’ approach allows for the integration of care for
high-cost patients who may be cared for by several
healthcare teams in different individual care pathways.
While this was a large-scale study, the cross-sectional
ﬁndings relate to one region of England. The patterns
of transitions may differ in other regions, especially as
services moved to different integrated models, but the
relative associations for multimorbid groups compared
with the index groups provide the best available esti-
mates on the impact on transitions and costs. These cost
estimations and relative are conservative as the reference
comparison groups had one of the two multimorbid
conditions, whereas a non-index reference group
without either pair condition would have magniﬁed the
relative cost differences. While new integrated models of
care are developing,20 such care will still need to differ-
entiate between the acute health needs of the patient
with a chronic disease, addressed by specialist interven-
tion, and the chronic health needs and monitoring that
will be addressed by general practice and community
teams. The study deﬁnitions also focused on pairs of
conditions but all groups were not exclusive, and there
was some overlap. For example, diabetes was paired with
HT, CHD and CKD, which indicates an overlap, but
Table 4 Multimorbidity transitions across A&E episodes and hospital admissions and associated costs over 3 years
Study groups
3-year AE
£ costs
Mean (SD)
Adjusted-regression*
estimates £ (SE) p Value
3-year IP £ costs
Mean (SD)
Adjusted-regression*
estimates £ (SE) p Value
HT+ DM− 55 (132) 0 1647 (4085) 0
DM+ HT− 69 (162) 20 (2) <0.001 2061 (4490) 595 (68) <0.001
HT and DM 69 (152) 14 (2) <0.001 2289 (4585) 607 (48) <0.001
DM+ CHD− 57 (124) 0 1825 (3977) 0
CHD+ DM− 84 (175) 22 (2) <0.001 2512 (5825) 431 (73) <0.001
DM and CHD 104 (219) 42 (3) <0.001 3372 (5789) 1270 (101) <0.001
DM+ CKD− 60 (143) 0 1850 (3996) 0
CKD+ DM− 80 (144) 4 (2) 0.14 2559 (4380) 403 (73) <0.001
DM and CKD 105 (190) 30 (3) <0.001 3642 (6063) 1480 (97) <0.001
COPD+ CHD− 96 (214) 0 2642 (4814) 0
CHD+ COPD− 81 (180) −13 (4) <0.001 2537 (5812) −152 (92) 0.097
COPD and CHD 138 (219) 40 (5) <0.001 3992 (5775) 1158 (151) <0.001
COPD+ CHF− 100 (211) 0 2769 (4925) 0
CHF+ COPD− 120 (192) 17 (5) <0.001 3877 (5732) 904 (125) <0.001
CHF and COPD 166 (242) 64 (8) <0.001 4901 (6199) 1954 (206) <0.001
CHF+ CKD− 108 (176) 0 3282 (4880) 0
CKD+ CHF− 75 (139) −31 (4) <0.001 2477 (4404) −629 (114) <0.001
CKD and CHF 164 (238) 52 (5) <0.001 5344 (6907) 2116 (163) <0.001
*Adjusted for age, gender and deprivation as measured by the Index of Multiple deprivation.
A&E, accident and emergency; CHD, coronary heart disease; CHF, chronic heart failure; CKD, chronic kidney disease; COPD, chronic
obstructive pulmonary disease; DM, diabetes mellitus; HT, hypertension.
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these results showed that different pairs with the same
index condition (eg, diabetes) have distinct associations
with healthcare transitions and costs.
The chronic disease registers from general practice
were part of the local and national initiatives, and such
data are now used widely in performance and payment
reporting, and healthcare studies.19 The healthcare tran-
sition data are also part of national performance and
payment reporting, and have also been used in health-
care studies. The recording of these transition episodes
(A&E or hospital admission) will be accurate as the
healthcare costs are based on the HRG allocated to each
individual patient, which is part of the cost transaction
process between the healthcare commissioner (PCT)
and the provider (hospital). Furthermore, the transi-
tions data and cost data are part of the national valid-
ation processes.16 21 In this study, the primary objective
was to test the clinical hypothesis that different multi-
morbidity pairs showed variations in overall healthcare
transitions, and therefore it does not include the
attempt to characterise the precise nature of each transi-
tion episode. The estimated costs for these patient popu-
lations are also an underestimate since they do not
include ongoing healthcare costs in general practice
and community care.
Previously, there have been few studies on multimor-
bidity and costs in speciﬁc settings,22 23 but there is a
lack of healthcare transitions data, and the hypothesis
that a study of speciﬁc ‘disease pairs’ may provide
insight into healthcare presentation and costs has not
been previously tested. Much of the current multimor-
bidity research has focused on the ‘burden’ as exempli-
ﬁed by the number of conditions that patients
experience, but the key limitation with the ‘counting’
approach is the lack of differentiation of how it links
into the current individual disease-designed pathways.
Arguably, it is better to conceptualise this issue into
‘which pairs’ and link it practically to the individual
disease pathways, which have been devised in terms of
the chronic disease model of care.24 The notion of
chronic disease and depression has notably been well
constructed in the psychiatric ﬁeld.25 This ‘disease pair’
approach provides a simple and clinically intuitively
approach that can be readily used in actual clinical prac-
tice, as well as a means by which local policy decisions
can incorporate estimated costs for healthcare
transitions.
This cross-sectional study provides the basis for the
innovative linking of data and understanding the health-
care ‘journey’ for the patient with different chronic dis-
eases. Further studies would address issues such as
multiple healthcare transitions, combining different
interfaces (eg, identifying patients who attend A&E
regularly and are admitted regularly) and the under-
lying and precise clinical reasons for the healthcare
costs. For example, healthcare transitions may cover
community care, and wider transitions could include
social care. The associations shown in this study also
need to be complemented by the temporal investigation
between chronic disease pairs and subsequent impact
on the time between healthcare transitions.
In conclusion, our study showed that speciﬁc multi-
morbid pairs compared with their index morbidity indi-
cated the level of transitions across healthcare interfaces
and the associated total healthcare costs. Identiﬁcation
of the multimorbidity type and linkage of information
across interfaces provides opportunities for targeted
intervention and delivery of cost-effective integrated
care.
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